Stanley M. Marks

1.2k total citations
32 papers, 777 citations indexed

About

Stanley M. Marks is a scholar working on Genetics, Pathology and Forensic Medicine and Hematology. According to data from OpenAlex, Stanley M. Marks has authored 32 papers receiving a total of 777 indexed citations (citations by other indexed papers that have themselves been cited), including 13 papers in Genetics, 9 papers in Pathology and Forensic Medicine and 9 papers in Hematology. Recurrent topics in Stanley M. Marks's work include Chronic Lymphocytic Leukemia Research (12 papers), Lymphoma Diagnosis and Treatment (9 papers) and Chronic Myeloid Leukemia Treatments (5 papers). Stanley M. Marks is often cited by papers focused on Chronic Lymphocytic Leukemia Research (12 papers), Lymphoma Diagnosis and Treatment (9 papers) and Chronic Myeloid Leukemia Treatments (5 papers). Stanley M. Marks collaborates with scholars based in United States, Japan and France. Stanley M. Marks's co-authors include Ronald P. McCaffrey, David Baltimore, Natalia González, Angela Lu, Araya Puwanant, Saša Živković, Jarushka Naidoo, Michael Boyiadzis, Kenneth A. Foon and Ahmad A. Tarhini and has published in prestigious journals such as New England Journal of Medicine, Journal of Clinical Oncology and Blood.

In The Last Decade

Stanley M. Marks

32 papers receiving 730 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Stanley M. Marks United States 14 356 299 264 240 166 32 777
Carmen Pedro Spain 15 314 0.9× 413 1.4× 301 1.1× 392 1.6× 126 0.8× 27 885
SH Nantel Canada 13 268 0.8× 366 1.2× 283 1.1× 473 2.0× 128 0.8× 20 847
Ohad Benjamini Israel 15 392 1.1× 281 0.9× 274 1.0× 247 1.0× 199 1.2× 56 920
P Coser Italy 15 215 0.6× 324 1.1× 339 1.3× 490 2.0× 154 0.9× 38 914
Niels Smedegaard Andersen Denmark 13 313 0.9× 499 1.7× 412 1.6× 222 0.9× 243 1.5× 38 834
Bernadette Corront France 15 258 0.7× 327 1.1× 266 1.0× 464 1.9× 117 0.7× 28 797
Amin Alousi United States 12 218 0.6× 294 1.0× 356 1.3× 558 2.3× 272 1.6× 16 886
T. Economopoulos Greece 18 446 1.3× 318 1.1× 359 1.4× 382 1.6× 210 1.3× 45 1.1k
Craig C. Childs United States 17 374 1.1× 407 1.4× 301 1.1× 308 1.3× 209 1.3× 25 911
G. J. Ossenkoppele Netherlands 18 135 0.4× 269 0.9× 308 1.2× 309 1.3× 218 1.3× 51 832

Countries citing papers authored by Stanley M. Marks

Since Specialization
Citations

This map shows the geographic impact of Stanley M. Marks's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Stanley M. Marks with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Stanley M. Marks more than expected).

Fields of papers citing papers by Stanley M. Marks

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Stanley M. Marks. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Stanley M. Marks. The network helps show where Stanley M. Marks may publish in the future.

Co-authorship network of co-authors of Stanley M. Marks

This figure shows the co-authorship network connecting the top 25 collaborators of Stanley M. Marks. A scholar is included among the top collaborators of Stanley M. Marks based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Stanley M. Marks. Stanley M. Marks is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Barrientos, Jacqueline C., Ayed O. Ayed, Bruno Fang, et al.. (2023). Results from a Real-World Multicenter Analysis of 482 Patients with Chronic Lymphocytic Leukemia Treated with Ibrutinib: A Look at Racial Differences. Targeted Oncology. 18(5). 727–734. 1 indexed citations
2.
Kuang, Chaoyuan, Yongseok Park, Ryan C. Augustin, et al.. (2022). Pembrolizumab plus azacitidine in patients with chemotherapy refractory metastatic colorectal cancer: a single-arm phase 2 trial and correlative biomarker analysis. Clinical Epigenetics. 14(1). 3–3. 42 indexed citations
3.
Gordan, Lucio, et al.. (2021). Daratumumab Utilization and Cost Analysis among Patients with Multiple Myeloma in a US Community Oncology Setting. Future Oncology. 18(3). 301–309. 5 indexed citations
4.
Marks, Stanley M. & Jarushka Naidoo. (2021). Antibody drug conjugates in non-small cell lung cancer: An emerging therapeutic approach. Lung Cancer. 163. 59–68. 29 indexed citations
5.
Hou, Jing‐Zhou, Kellie Ryan, Bruno Fang, et al.. (2020). Dose Reductions and Discontinuations with Chronic Lymphocytic Leukemia (CLL) Patients Receiving Ibrutinib in Community and Academic Settings. Blood. 136(Supplement 1). 12–13. 1 indexed citations
6.
Schwartzberg, Lee S., Stanley M. Marks, Nashat Gabrail, Robert B. Geller, & Jonathan Kish. (2019). Real-world effectiveness of palonosetron-based antiemetic regimens: preventing chemotherapy-induced nausea and vomiting. Journal of Comparative Effectiveness Research. 8(9). 657–670. 5 indexed citations
7.
Garcia, Christine, Edward Chu, Stanley M. Marks, et al.. (2019). Standardization of Inpatient CPR Status Discussions and Documentation Within the Division of Hematology-Oncology at UPMC Shadyside: Results From PDSA Cycles 1 and 2. Journal of Oncology Practice. 15(8). e746–e754. 2 indexed citations
8.
Manoj, P, et al.. (2018). Patterns of Inpatient Care and Outcomes for Multiple Myeloma in 2014: A National Inpatient Sample Analysis. Blood. 132(Supplement 1). 4748–4748. 1 indexed citations
9.
Garcia, Christine, et al.. (2018). Standardization of inpatient CPR/code status discussions and documentation within the division of hematology-oncology at UPMC Shadyside.. Journal of Clinical Oncology. 36(15_suppl). e18776–e18776. 1 indexed citations
10.
González, Natalia, Araya Puwanant, Angela Lu, Stanley M. Marks, & Saša Živković. (2017). Myasthenia triggered by immune checkpoint inhibitors: New case and literature review. Neuromuscular Disorders. 27(3). 266–268. 81 indexed citations
11.
Lee, James J., Weijing Sun, Nathan Bahary, et al.. (2017). Phase 2 study of pembrolizumab in combination with azacitidine in subjects with metastatic colorectal cancer.. Journal of Clinical Oncology. 35(15_suppl). 3054–3054. 26 indexed citations
12.
Roth, Christine G., Amanda Gillespie-Twardy, Stanley M. Marks, et al.. (2016). Flow Cytometric Evaluation of Double/Triple Hit Lymphoma. Oncology Research Featuring Preclinical and Clinical Cancer Therapeutics. 23(3). 137–146. 14 indexed citations
13.
Geller, Robert B., Trent McLaughlin, Madhuri Bajaj, et al.. (2016). Real-world effectiveness of palonosetron within a three-drug regimen to prevent chemotherapy induced nausea and vomiting (CINV) following highly emetogenic chemotherapy (HEC).. Journal of Clinical Oncology. 34(15_suppl). e18231–e18231. 1 indexed citations
14.
Raptis, Anastasios, Jing‐Zhou Hou, Rafic Farah, et al.. (2015). Inferior outcome after allogeneic transplant in first remission in high‐risk AML patients who required more than two cycles of induction therapy. American Journal of Hematology. 90(8). 715–718. 6 indexed citations
15.
Sathanoori, Malini, et al.. (2007). Derivative (14)t(11;14)(q13;q32)t(11;14)(p11.2;p11.2): a novel unbalanced variant of the t(11;14)(q13;q32) translocation in mantle cell lymphoma. Cancer Genetics and Cytogenetics. 172(2). 158–164. 2 indexed citations
16.
17.
Young, Wanda W., et al.. (1996). Dissemination of Clinical Results. Medical Care. 34(10). 1003–1017. 38 indexed citations
18.
Granato, Jerome E., et al.. (1993). A unique chromosomal abnormality in idiopathic hypereosinophilic syndrome presenting with cardiac involvement. American Heart Journal. 126(1). 246–248. 11 indexed citations
19.
Long, John C., Ronald P. McCaffrey, Stanley M. Marks, Alan C. Aisenberg, & Patrick C. Kung. (1979). Terminal deoxynucleotidyl transferase positive lymphoblastic lymphoma.A study of 15 cases. Cancer. 44(6). 2127–2139. 29 indexed citations
20.
Yanovich, Saul, Stanley M. Marks, David S. Rosenthal, William C. Moloney, & Stuart F. Schlossman. (1979). Cell-surface characteristics of hairy cell leukemia in seven patients. Cancer. 43(6). 2348–2351. 7 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Carmen Pedro Breakdown of academic impact, for papers by SH Nantel Breakdown of academic impact, for papers by Ohad Benjamini Breakdown of academic impact, for papers by P Coser Breakdown of academic impact, for papers by Niels Smedegaard Andersen Breakdown of academic impact, for papers by Bernadette Corront Breakdown of academic impact, for papers by Amin Alousi Breakdown of academic impact, for papers by T. Economopoulos Breakdown of academic impact, for papers by Craig C. Childs Breakdown of academic impact, for papers by G. J. Ossenkoppele
Rankless by CCL
2026